Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Tax Provisions (2021 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Tax Provisions for 6 consecutive years, with -$16000.0 as the latest value for Q1 2026.

  • For Q1 2026, Tax Provisions rose 27.27% year-over-year to -$16000.0; the TTM value through Mar 2026 reached -$169000.0, down 482.76%, while the annual FY2025 figure was -$175000.0, 297.73% down from the prior year.
  • Tax Provisions hit -$16000.0 in Q1 2026 for Barinthus Biotherapeutics, up from -$57000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $3000.0 in Q4 2024 and bottomed at -$2.0 million in Q4 2022.
  • Average Tax Provisions over 5 years is -$457705.9, with a median of -$71000.0 recorded in 2025.
  • Year-over-year, Tax Provisions plummeted 9528.57% in 2022 and then soared 100.37% in 2024.
  • Barinthus Biotherapeutics' Tax Provisions stood at -$2.0 million in 2022, then skyrocketed by 59.39% to -$820000.0 in 2023, then soared by 100.37% to $3000.0 in 2024, then tumbled by 2000.0% to -$57000.0 in 2025, then surged by 71.93% to -$16000.0 in 2026.
  • According to Business Quant data, Tax Provisions over the past three periods came in at -$16000.0, -$57000.0, and -$71000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.